TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05709327

Intervention type: OTHER
Group type: OTHER
Intervention: Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)
Description: Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
Study: NCT06332339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 16055 NFL delta Gly4 trimer
Description: 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
Study: NCT06218186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device: Wesper Lab Home Sleep Test
Description: Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
Study: NCT05009446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: endoscopic surgery or endoscope-assisted surgery open surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy
Description: radiotherapy was administrated before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
Study: NCT06332339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 16055 NFL delta Gly4 trimer
Description: 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 16055 NFL delta Gly4 trimer
Description: 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env145NFL, 5 x 108 viral particles (vp)
Description: to be administered intranasally (IN) (0.07 mL into 1 nostril)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env145NFL, 5 x 108 viral particles (vp)
Description: to be administered intranasally (IN) (0.07 mL into 1 nostril)
Study: NCT05021835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab B
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab C
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ziltivekimab B)
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ziltivekimab C)
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Study: NCT05916937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab 300 mg every four weeks
Description: Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab 300 mg every six weeks
Description: Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Study: NCT05810597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Dose Pen
Description: Used to administer tirzepatide SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Dose Pen
Description: Used to administer tirzepatide SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-use Prefilled Pen
Description: Used to administer tirzepatide SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-use Prefilled Pen
Description: Used to administer tirzepatide SC
Study: NCT05136027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Low-intensity interval training and resistance exercise
Study: NCT04825600

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-Toxoplasma gondii IgG and IgM dosage
Description: blood sample performed to check the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-Toxoplasma gondii IgG and IgM dosage
Description: blood sample performed to check the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-Toxoplasma gondii IgG and IgM dosage
Description: blood sample performed to check the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-Toxoplasma gondii IgG and IgM dosage
Description: blood sample performed to check the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cellular test
Description: blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cellular test
Description: blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cellular test
Description: blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cellular test
Description: blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
Study: NCT06568575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experiment of music
Description: Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experiment of exercise
Description: Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
Study: NCT04908046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
Description: Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly.
Study: NCT04882046

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: collection of socio-demographic, clinical and biological data.
Study: NCT05655052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Group
Description: At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using distraction cards
Description: At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care.
Study: NCT05021081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRP-200
Description: JJVC Investigational Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRP-200
Description: JJVC Investigational Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day
Description: JJVC Marketed Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day
Description: JJVC Marketed Contact Lens
Study: NCT04697056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06397833

Intervention type: DEVICE
Intervention: Acorai ICPM system
Description: Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
Study: NCT06634537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: insoles hard, soft and barefoot
Description: Primary Outcome Measure:~1. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]
Study: NCT04357353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: PRP will be used in the experimental arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Sham Injection
Description: sham injection
Study: NCT05807724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based fall-prevention strategy
Description: Written education material and Phone-Based Fall-Prevention Strategy
Study: NCT06535763

Intervention type: OTHER
Intervention: professional caregiver
Description: Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist.
Study: NCT05712317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame Intervention
Description: 8-week exergame-based intervention 3x per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity endurance exercise
Description: 8-week moderate-intensity endurance exercise 3x per week
Study: NCT05807724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-visit fall prevention strategy
Description: Written education material and Home visit-Based Fall-Prevention Strategy
Study: NCT04929236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
Study: NCT03803540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation via duodenal infusion
Study: NCT05103332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Olmesartan administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Olmesartan administered orally
Study: NCT04905693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled Treprostinil (6 mcg/breath) administered QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study: NCT06268028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Discharge training
Study: NCT05103332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indapamide
Description: Indapamide administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indapamide
Description: Indapamide administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection
Study: NCT06512519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)
Study: NCT04837833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
Study: NCT04580420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Monthly dosing throughout study period
Study: NCT05103332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection
Study: NCT05379946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: IN10018 orally once daily at approximately the same time each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: IN10018 orally once daily at approximately the same time each day
Study: NCT05858294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy programme
Description: This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
Study: NCT06262555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial PDT peripheral lung tumor ablation
Description: Transbronchial lung tumor ablation with Photodynamic therapy
Study: NCT06169293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-AM-WELL
Description: The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours.
Study: NCT05117333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder (information letter)
Description: Reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder (information letter)
Description: Reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder (information letter)
Description: Reminders
Study: NCT05424380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered
Study: NCT06001762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4 and CDK6 inhibitor, tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Selective estrogen receptor modulator, taken orally per institutional standard of care
Study: NCT05077072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC
Study: NCT06001762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Steroidal aromatase inhibitor, taken orally per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
Study: NCT06227091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: acute dose of beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: depleted nitrate beetroot juice
Study: NCT05570630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAX-MOM COVID-19 Intervention
Description: The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard vaccine education and processes provided to patients by obstetric practices.